[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613848":3},{"organization":4,"outcomesModule":7,"designInfo":55,"detailedDescription":54,"studyPopulation":54,"armGroups":61,"interventions":68,"overallOfficials":54,"centralContacts":74,"locations":80,"responsibleParty":98,"collaborators":54,"id":102,"slug":54,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":54,"enrollmentInfo":111,"targetDuration":54,"studyType":114,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":82,"whyStopped":54,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Pusan National University Yangsan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":54},[9],{"measure":10,"description":11,"timeFrame":12},"UPDRS","Unified Parkinson's Disease Rating Scale","Change in UPDRS from baseline to post 30 sessions (up to approximately 10 weeks). The UPDRS ranges from 0 to 199, with higher scores indicating greater symptom severity.",[14,18,22,26,30,34,38,42,46,50],{"measure":15,"description":16,"timeFrame":17},"BBS","Berg Balance Scale","Change in Berg Balance Scale scores from baseline to post 30 sessions (up to approximately 10 weeks). The BBS ranges from 0 to 56, with higher scores indicating better balance performance.",{"measure":19,"description":20,"timeFrame":21},"Grip strength and pinch strength test","Grasp, tip pinch \\& three jaw chuck","Change in Grip strength and pinch strength from baseline to post 30 sessions (up to approximately 10 weeks). Higher scores indicate better hand function.",{"measure":23,"description":24,"timeFrame":25},"FRT","Functional Reach Test","Change in Functional Reach Test scores from baseline to post 30 sessions (up to approximately 10 weeks). Higher scores indicate better hand function.",{"measure":27,"description":28,"timeFrame":29},"TUG","Timed Up and Go","Change in Timed Up and Go test scores from baseline to post 30 sessions (up to approximately 10 weeks). Lower scores indicate better functional mobility.",{"measure":31,"description":32,"timeFrame":33},"CTRS","Clinical Rating Scale for Tremor","Change in CRTS scores from baseline to post 30 sessions (up to approximately 10 weeks). The score ranges from 0 to 160, with higher scores indicating more severe tremor symptoms.",{"measure":35,"description":36,"timeFrame":37},"SVLT","Seoul verbal learning test","Change in SVLT scores from baseline to post 30 sessions (up to approximately 10 weeks). The scores ranging from 0 to 36, where higher scores reflect better memory performance.",{"measure":39,"description":40,"timeFrame":41},"RCFT","Rey complex figure test","Change in RCFT scores from baseline to post 30 sessions (up to approximately 10 weeks). Higher scores indicate better visuospatial and memory performance.",{"measure":43,"description":44,"timeFrame":45},"DST","Digit span test","Change in DST scores from baseline to post 30 sessions (up to approximately 10 weeks). Higher scores indicate better performance.",{"measure":47,"description":48,"timeFrame":49},"TMT","Trail making test","Change in TMT scores from baseline to post 30 sessions (up to approximately 10 weeks). Faster completion times (i.e., lower scores) indicate better cognitive function.",{"measure":51,"description":52,"timeFrame":53},"K-CWST","Korean-Color word stroop test","Change in K-CWST scores from baseline to post 30 sessions (up to approximately 10 weeks). Faster completion times (i.e., lower scores) indicate better cognitive function.",null,{"allocation":56,"interventionModel":57,"interventionModelDescription":54,"primaryPurpose":58,"observationalModel":54,"timePerspective":54,"maskingInfo":59},"NA","SINGLE_GROUP","TREATMENT",{"masking":60,"maskingDescription":54,"whoMasked":54},"NONE",[62],{"label":63,"type":64,"description":65,"interventionNames":66},"Parkinson","EXPERIMENTAL","Participants received whole-body PBM therapy once daily (20 minutes per session), three times per week, for approximately 10 weeks, totaling 30 sessions.",[67],"Device: Photobiomodulation",[69],{"type":70,"name":71,"description":72,"armGroupLabels":73,"otherNames":54},"DEVICE","Photobiomodulation","Participants received whole-body PBM therapy over approximately 10 weeks (three sessions per week, once daily, 20 minutes per session), with each session using a randomly selected wavelength of either 660 nm, 850 nm, or 940 nm (±20%).",[63],[75],{"name":76,"role":77,"phone":78,"phoneExt":54,"email":79},"Jisoo Baik","CONTACT","082+055-360-4159","zisoo@pusan.ac.kr",[81],{"facility":5,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":54,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"RECRUITING","Yangsan","Gyeongsangnam-do","50612","South Korea",{"type":88,"coordinates":89},"Point",[90,91],129.03358,35.34199,{"lat":91,"lon":90},[94],{"name":95,"role":77,"phone":96,"phoneExt":54,"email":97},"Youjin Jeong","+82-55-360-4720","gamza33@naver.com",{"type":99,"investigatorFullName":100,"investigatorTitle":101,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"PRINCIPAL_INVESTIGATOR","Yong-il Shin","Professor","100613848",false,"NCT07271927","Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease","Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease","PBM","Inclusion Criteria:\n\n* Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination\n* Adults aged 40 years or older\n* Individuals able to walk independently\n\nExclusion Criteria:\n\n* Individuals with severe cognitive impairment (Korean Mini-Mental State Examination \\[K-MMSE\\] score ≤ 9) making it difficult to understand and perform tasks\n* Patients with dementia other than Parkinson's disease dementia\n* Individuals with implanted medical or other electronic devices\n* Individuals with severe neuropsychiatric disorders\n* Individuals treated for alcohol dependence within 6 months prior to screening\n* Individuals with a history of suicide attempts\n* Individuals with a history of seizures\n* Individuals experiencing dyspnea while sitting at rest\n* Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses\n* Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid\n* Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months\n* Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods\n* Pregnant or breastfeeding women\n* Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above","ALL","40 Years",{"count":112,"type":113},15,"ESTIMATED","INTERVENTIONAL",[56],"This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.",[118],"PARKINSON DISEASE (Disorder)",[71,120,121,122,123],"Parkinson disease","cognition","motor function","light theraphy","2025-11-26",{"date":126,"type":127},"2025-12-09","ACTUAL",{"date":129,"type":127},"2025-02-12",{"date":131,"type":113},"2025-12-31",{"name":5,"class":6},1]